Lunch Details
Our first collaboration with The Armchair Analyst newsletter - Control Bionics. Control Bionics delivers objective, non-invasive neural-signal technology, proven in clinical environments, and built to scale across performance, rehabilitation, medical, research, and assistive communication. Surface electromyography detects the electrical activity produced by muscles. These signals, generated at the neuromuscular junction and measurable at the skin’s surface, carry precise information about muscle activation, intent, and physiological state. No implant. No surgery. No modification to the body. The Control Bionics platform captures these signals through medical-grade sensors, processes them through proprietary algorithms, and converts them into structured, decision-ready data. What begins as an electrical impulse at the surface of the skin becomes measurable insight: usable in clinical assessment, research analysis, rehabilitation monitoring, and access to assistive communication.
Control Bionics is an ASX-listed neurotechnology company with a validated platform, established regulatory clearances, and active deployment across clinical, research, and performance markets.
